Results of two new studies support the use of the intravenous formulation of the antiepileptic drug (AED) Vimpat® for patients requiring add-on therapy in clinical settings where oral AED therapy is temporarily not feasible. These data, which were presented by UCB at the 63rd annual meeting of the American Epilepsy Society in Boston, further clarify the role of intravenous Vimpat in the institutional setting.
One study shows that patients can be transitioned from intravenous Vimpat to the oral formulation, while maintaining steady, therapeutic plasma levels.
"This study shows that intravenous Vimpat is generally well tolerated across a range of doses and infusion durations as a replacement for oral therapy in add-on epilepsy therapy. This will help patients receive Vimpat in clinical settings where administration of an oral epilepsy therapy is not possible, such as emergency rooms or those related to surgery," said study author Gregory Krauss, MD, Department of Neurology, Johns Hopkins Epilepsy Center in Baltimore, MD. "This study helps clinicians understand what to expect when initiating and monitoring intravenous treatment in patients who are Vimpat-naive or who need to substitute oral Vimpat with an intravenous formulation."
A second study provides data on administration of a single intravenous loading dose of Vimpat over 15 minutes, followed by the equivalent daily oral dose administered twice daily.
Vimpat was launched in the U.S. in May 2009 as an add-on therapy for the treatment of partial-onset seizures in people with epilepsy who are 17 years and older. Vimpat has a novel mechanism of action that is different from all currently available AEDs. Vimpat is available as oral tablets and as an intravenous (IV) infusion to allow for consistent treatment in a hospital or emergency setting.
Vimpat can be initiated with either oral or intravenous administration. The initial dose should be 50 mg twice daily (100 mg per day). Vimpat can be increased weekly by 100 mg/day, given as two divided doses, up to the recommended maintenance dose of 200 to 400 mg/day. When switching from oral Vimpat, the initial total daily intravenous dosage of Vimpat should be equivalent to the total daily dosage and frequency of oral Vimpat and should be infused intravenously over a period of 30 to 60 minutes. At the end of the intravenous treatment period, the patient may be switched to Vimpat oral administration at the equivalent daily dosage and frequency of the intravenous administration.
Summary of Intravenous Vimpat Data Presented at 2009 AES Annual Meeting
Abstract: Pharmacokinetic evaluation of intravenous lacosamide as short-term replacement for oral lacosamide in partial-onset seizures